Russian pharmaceutical companies Sotex and Rapharma have introduced a new epilepsy drug, Novolera EPI (INN: lacosamide), to the market, Sotex’ public relations service told GxP News.
Novolera EPI is a next-generation sodium channel blocker indicated for epilepsy treatment in adults, adolescents, and children over 4 years old. The drug is available in 50, 100, 150, and 200 mg tablets, designed to facilitate convenient dose titration during therapy.
It can be used as monotherapy or adjunctive treatment for partial-onset seizures (involving one brain hemisphere) and idiopathic generalized epilepsy (involving all brain areas). Another approved indication is adjunctive therapy for primary generalized tonic-clonic seizures with loss of consciousness.
“Novolera EPI is an important tool for epileptologists. Its use expands opportunities for personalized treatment and improves epilepsy therapy outcomes,” the statement noted.
Earlier it was reported that Sotex launched sales of Russia’s first generic sugammadex.